Anti-Human HLA-DRA Recombinant Antibody (1D09C3) (HM812107)

Name: Anti-Human HLA-DRA Recombinant Antibody (1D09C3)
Brand: abinScience
SKU: HM812107
Price: 118 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

50ug
100ug

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HM812107
Species reactivity	Human
Applications	FCM
Host species	Mouse
Isotype	IgG1, kappa
Clone ID	1D09C3
Clonality	Monoclonal
Target	HLA-DRA1, MHC class II antigen DRA, HLA-DRA, HLA class II histocompatibility antigen, DR alpha chain
Endotoxin level	Please contact with the lab for this information.
Purity	>95% as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P01903
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Background	HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA) is a ~28 kDa protein. An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA-DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells. Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes. In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins. 1. Shams, H. et al. (2004) Journal of immunology (Baltimore, Md. : 1950) 173, 1966-77. PMID: 15265931 2. Röhn, TA. et al. (2004) Nature immunology 5, 909-18. PMID: 15322540 3. Deng, L. et al. (2007) Nature immunology 8, 398-408. PMID: 17334368 4. Kwok, WW. et al. (2012) Journal of immunology (Baltimore, Md. : 1950) 188, 2537-44. PMID: 22327072 5. Scally, SW. et al. (2013) The Journal of experimental medicine 210, 2569-82. PMID: 24190431 6. Muehling, LM. et al. (2016) Journal of immunology (Baltimore, Md. : 1950) 197, 3214-3224. PMID: 27591323 7. Galperin, M. et al. (2018) Science immunology 3. PMID: 29884618 8. Abelin, JG. et al. (2019) Immunity 51, 766-779.e17. PMID: 31495665 9. Stern, LJ. et al. (1994) Nature 368, 215-21. PMID: 8145819 10. Kropshofer, H. et al. (1997) Immunity 6, 293-302. PMID: 9075930
Note	For research use only.

Images

Bioactivity

SEC-HPLC detection for Anti-Human HLA-DRA Antibody (1D09C3).
Flow Cytometry

Flow-cytometry using anti-human HLA-DRA antibody. Human U-87 cell line were stained with an irrelevant antibody (Green Histogram) or an anti-human HLA-DRA antibody monoclonal antibody (Catalog # HM812107 , Red Histogram) at a concentration of 20 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a CoraLite488 conjugated goat anti-mouse antibody (Catalog # MF690314) and cells analysed on a NovoCyte Flow Cytometer.